ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients

C. Rosso Felipe, L. Viana, M. Pontello Cristelli, M. Nakamura, L. Ramagnoli, S. Braga, V. Lima, A. Carnevalle, D. Casarini, J. Medina Pestana, H. Tedesco Silva Junior

Hospital do Rim, Nephrology Division, EPM - UNIFESP, São Paulo, Brazil

Meeting: 2019 American Transplant Congress

Abstract number: A273

Keywords: Kidney transplantation, Pharmacokinetics, Sirolimus (SLR)

Session Information

Session Name: Poster Session A: Kidney Immunosuppression: Novel Regimens and Drug Minimization

Session Type: Poster Session

Date: Saturday, June 1, 2019

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall C & D

*Purpose: Despite distinct pharmacokinetic properties, SRL and EVR bind to the same intracellular target protein, suggesting that equivalent blood concentrations may exert similar pharmacodynamic effect.

*Methods: Methods: This large, single center, prospective randomized trial compares the efficacy, safety, therapeutic drug monitoring and an array of candidate biomarkers of the use of SRL (3 mg QD adjusted to maintain concentrations between 4 to 8 ng/mL), EVR (3 mg BID adjusted to maintain concentrations between 4 to 8ng/mL), or MPA (720 mg BID) in kidney transplant recipients receiving 3 mg/kg r-ATG induction therapy, tacrolimus and faster prednisone taper (Clinicaltrials.govNCT03468478). Our hypothesis is that similar initial 3 mg doses of SRL (QD) and EVR (BID) would provide comparable blood concentrations and similar responses to dose adjustments, despite the differences in pharmacokinetic profiles. Methods: This preliminary analysis included 153 adult recipients of first kidney transplants with at least one month of follow up. First dose adjustments consisted of a 30% increase in drug dose for all patients with blood concentrations below 4 ng/ml. Subsequent dose adjustments were made twice a week to achieve blood concentrations of 6 ng/ml.

*Results: There were no differences in demographic characteristics of the study population. At day 3 mean trough concentrations of SRL and EVR were comparable (3.2±1.3 vs. 3.8±0.9 ng/mL, p=0.084) although a low percentage of patients showed concentration above 4 ng/ml (20% vs. 22%, respectively). From day 3 to day 28 a higher proportion of patients receiving SRL reached target therapeutic concentration compared to EVR (Figure). Compared to day 3, at day 28 SRL doses were 20% higher (3.3±0.8 mg/day) while EVR dose were 60% higher (4.8±1.4 mg/day), producing mean trough concentrations of (8.0±4.0 and 6.3±1.7 ng/mL, p= 0.023), respectively. Higher increases in dose-corrected concentrations from day 1 to 28 were observed with SRL (1.3±0.5 to 2.6±1.5 ng/mL/mg) compared to EVR (1.2±0.4 to 1.3±0.5).

*Conclusions: Despite using similar initial doses and therapeutic monitoring strategies, a higher proportion of patients receiving SRL reach therapeutic drug concentrations faster with lower doses compared to those receiving EVR.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Felipe CRosso, Viana L, Cristelli MPontello, Nakamura M, Ramagnoli L, Braga S, Lima V, Carnevalle A, Casarini D, Pestana JMedina, Junior HTedescoSilva. Comparison of Initial Sirolimus (SRL) and Everolimus (EVR) Exposure Patterns in Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-initial-sirolimus-srl-and-everolimus-evr-exposure-patterns-in-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences